Clotrimazole cream

Information

  • Patent Grant
  • 4775678
  • Patent Number
    4,775,678
  • Date Filed
    Thursday, May 8, 1986
    38 years ago
  • Date Issued
    Tuesday, October 4, 1988
    35 years ago
Abstract
An oil-in-water cream or lotion emulsion formulation containing clotrimazole having improved antifungal properties containing various amounts of clotrimazole, petrolatum, cetearyl alcohol, propylene glycol, and ceteth-20, with or without other additional ingredients.
Description

BACKGROUND
This invention relates to a cream or lotion formulation of clotrimazole having improved antifungal properties and superior penetrating properties.
CLotrimazole, 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole, described in U.S. Pat. No. 3,660,577, is an effective antifungal compound. However, to be optimally effective it must be brought into direct contact with the fungal infection being treated. Unfortunately, such infections are frequently located in hard to reach deeper skin layers, hyper-keratinized skin and/or nails. Hence, a clotrimazole containing formulation having a high degree of penetration enabling it to reach hard-to-reach fungal infections is highly desirable.
SUMMARY
The present invention provides antifungal percutaneous cream or lotion compositions, for administration to warm-blooded animals, including man, containing as the active antifungal ingredient an antifungal effective amount of clotrimazole. The compositions have superior penetrating properties, enhanced antifungal activity, and are optimally effective at a pH range of 5-7.
In addition to the active ingredient, clotrimazole, a specific combination of pharmaceutically acceptable adjuvants are in the formulation of this invention. The adjuvants must be chemically inert to the remaining ingredients.
The compositions with superior penetrating powers contain an innocuous vehicle with emollient occlusive properties, e.g., petrolatum; a bodying agent which gives a good feel on the skin, e.g., cetearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid and the like, with cetearyl alcohol preferred; a solubility enhancer for clotrimazole, e.g., propylene glycol, hexylene glycol, polyethylene glycol 400 and the like, with propylene glycol preferred; and a non-ionic surfactant which forms an oil-in-water emulsion cream base, e.g., ceteth 20, steareth-2, steareth-20 or mixtures thereof and the like, with ceteth 20 preferred; and water.
Optional ingredients in the compositions of this invention are buffers such as mono- and di-basic sodium phosphate, mineral oil, preservatives such as benzyl alcohol, stabilizers and other conventional excipients for topical creams and lotions so long as they do not deleteriously affect the penetrating properties.
The antifungal activity of the composition of this invention is about 2 to 3 times greater than is manifested by known clotrimazole containing compositions. The following are illustrative formulations of this invention:
______________________________________I. (a) 0.1 to 100 mg clotrimazole; (b) 100 to 300 mg petrolatum; (c) 50 to 120 mg cetearyl alcohol; (d) 50 to 200 mg propylene glycol; (e) 15 to 30 mg ceteth-20; and (f) water q.s. to 1 gram.II. 5 to 50 mg clotrimazole; 150 to 200 mg petrolatum; 60 to 80 mg cetearyl alcohol; 90 to 110 mg propylene glycol; 20 to 25 mg ceteth-20; and water q.s. to 1 gram.III. 40 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 22.5 mg ceteth-20; 100 mg propylene glycol; and water q.s. to 1 gram.IV. 30 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20;______________________________________
additional ingredients selected from the group consisting of 60 mg/g mineral oil, 10 mg/g benzyl alcohol, 0.35 mg/g anhydrous dibasic sodium phosphate, 5 mg/g monobasic sodium phosphate and combinations thereof; and
water q.s. to 1 gram.
______________________________________V. 20 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 60 mg mineral oil; 10 mg benzyl alcohol; 0.35 mg anhydrous dibasic sodium phosphate; 5 mg monobasic sodium phosphate; and water q.s. to 1 gram.VI. 50 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; and water q.s. to 1 gram.VII. 100 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20;______________________________________
additional ingredients selected from the group consisting of 20 mg/g mineral oil, 10 mg/g benzyl alcohol, 0.35 mg/g anhydrous dibasic sodium phosphate, 5 mg/g monobasic sodium phosphate and combination thereof; and
water q.s. to 1 gram.
______________________________________VIII. 40 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 20 mg mineral oil; 10 mg benzyl alcohol; 0.35 mg anhydrous dibasic sodium phosphate; 5 mg monobasic sodium phosphate; and water q.s. to 1 gram.IX. 0.1 to 100 mg clotrimazole; 100 to 300 mg petrolatum; 50 to 120 mg cetearyl alcohol; 50 to 200 mg propylene glycol; 15 to 30 mg ceteth-20; 10 mg/g preservative exclusive of benzyl alcohol; and water q.s. to 1 gram.X. 0.1 to 100 mg clotrimazole; 100 to 300 mg petrolatum; 50 to 120 mg cetearyl alcohol; 50 to 200 mg propylene glycol; 15 to 30 mg ceteth-20; 15-30 mg/g steareth-2 (Brij 72) and 15-30 mg/g steareth-20 (Brij 78); and water q.s. to 1 gram.XI. 40 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 0.5-5 mg/g buffer of citrate/sodium hydroxide and citrate/phosphate; and water q.s. to 1 gram.XII. 0.1 to 100 mg clotrimazole; 100 to 300 mg petrolatum; 50 to 120 mg cetearyl alcohol; 50 to 200 mg propylene glycol; 15 to 30 mg ceteth-20; 0.5-5 mg/g buffer of citrate/sodium hydroxide and citrate/phosphate; and water q.s. to 1 gram.XIII. 70 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 22.5 mg/g Brij 72 and 22.5 mg/g Brij 78; and water q.s. to 1 gram.XIV. 40 mg clotrimazole; 150 mg petrolatum; 24 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 10 mg/g preservative exclusive of benzyl alcohol; and water q.s. to 1 gram.XV. 40 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 60 mg mineral oil; 10 mg benzyl alcohol; 0.35 mg anhydrous dibasic sodium phosphate; 5 mg monobasic sodium phosphate; and water q.s. to 1 gram.XVI. 0.5 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 60 mg mineral oil; 10 mg benzyl alcohol; 0.35 mg anhydrous dibasic sodium phosphate; 5 mg monobasic sodium phosphate; and water q.s. to 1 gram.XVII. 0.1 mg clotrimazole; 150 mg petrolatum; 72 mg cetearyl alcohol; 100 mg propylene glycol; 22.5 mg ceteth-20; 60 mg mineral oil; 10 mg benzyl alcohol; 0.35 mg anhydrous dibasic sodium phosphate; 5 mg monobasic sodium phosphate; and water q.s. to 1 gram.______________________________________
As used herein:
"Cetearyl alcohol" is defined as a mixture of fatty alcohols consisting predominantly of cetyl and stearyl alcohols.
"Ceteth-20" is defined as having the polyethylene glycol ether of cetyl alcohol (q.v.) that conforms to the formula CH.sub.3 (CH.sub.2).sub.14 CH.sub.2 (OCH.sub.2 CH.sub.2).sub.n OH where n has an average value of 20.
"Brij 72" is "steareth-2" which is defined as the polyethylene glycol ether of stearyl alcohol (q.v.) that conforms to the formula:
CH.sub.3 (CH.sub.2).sub.16 CH.sub.2 (OCH.sub.2 CH.sub.2).sub.n OH
where n has an average value of 2.
"Brij 78" is "steareth-20" which is defined as the polyethylene glycol ether of stearyl alcohol (q.v.) that conforms to the formula:
CH.sub.3 (CH.sub.2).sub.16 CH.sub.2 (OCH.sub.2 CH.sub.2).sub.n OH
where n has an average value of 20.
Except for "clotrimazole" and water, all ingredients appearing in the specification and claims are defined in the CTFA Cosmetic Ingredient Dictionary, 3rd Edition, (1982), published by the Cosmetic, Toiletry and Fragrance Association, Inc. which is incorporated herein by reference.





BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph of the % efficacy based on the area under the curve vs. % concentration of clotrimazole in the claimed oil-in-water composition and in the commercial oil-in-water composition.





DETAILED DESCRIPTION OF THE INVENTION
The antifungal topical cream or lotion compositions of this invention contain about 0.1 to 100 mg/g, preferably about 10 to 30 mg/g, of clotrimazole as the active antifungal ingredient and as the combination of ingredients which are responsible for the superior penetrating properties and thus enhanced antifungal activity per unit of clotrimazole, about 100 to 300 mg/g of petrolatum, preferably 150 to 200 mg/g; about 50 to 120 mg/g of a bodying agent which imparts good feel, preferably about 60 to 80 mg/g, the preferred bodying agent is cetearyl alcohol; about 50 to 200 mg/g of a solubility and preservative enhancer, preferably about 90 to 100 mg/g, the preferred enhancer is propylene glycol; about 15 to 30 mg/g of a non-ionic surfacant which forms an oil-in-water emulsion cream base, preferably 20 to 25 mg/g, the preferred surfacant is ceteth-20.
Other optional ingredients can be added to act as preservatives, pH controllers, perfumes and the like. Typical suitable optional ingredients are mineral oil, about 20-60 mg/g; benzyl alcohol, about 10 mg/g; anhydrous dibasic sodium phosphate, about 0.35 mg/g; monobasic sodium phosphate, about 5 mg/g; about 10 mg/g of preservatives other than benzyl alcohol, e.g., sorbic acid, benzoic acid, methyl and ethyl parabens and the like; about 15-30 mg/g of Brij 72 and Brij 78; about 0.5-5 mg/g of a buffer of sodium citrate/sodium hydroxide and sodium citrate/mono- and dibasic sodium phosphate, to maintain the pH within the preferred range of about 5-7 pH.
The preferred essential ingredients and amounts thereof as shown below in Table I form anti-fungal oil-in-water emulsion creams which creams are cutaneously penetrating and impart enhanced antifungal activity.
TABLE I______________________________________TOPICAL ANTI-FUNGAL OIL-IN-WATERPENETRATING BASE Operable Concentration Preferred ConcentrationIngredients mg/g of the Formulation mg/g of the Formulation______________________________________Clotrimazole 0.1 to 100 30 to 50Petrolatum 100 to 300 150 to 200Cetearyl 50 to 120 60 to 80AlcoholPropylene 50 to 200 90 to 110GlycolCeteth 20 15 to 30 20 to 25Water q.s. for 1 gram q.s. for 1 gram______________________________________
Clotrimazole formulated in the oil-in-water emulsion cream bases (Table I) and in a commercial oil-in-water emulsion cream base, i.e. the antifungal cream "Lotrimin" marketed by Schering-Plough of the following composition
______________________________________Ingredient mg/g______________________________________Clotrimazole 0.2-1.0Cetyl esters wax 30.0Cetearyl Alcohol 100.0Sorbitan Monostearate 20.0Polysorbate 60* 15.0Octyl Dodecanol 135.00Benzyl Alcohol 10.00purified water q.s. to 1.0 g______________________________________ *(Polysorbate 60 is a mixture of stearate esters of sorbitol and sorbitol anhydrides, consisting predominately of the monoester, condensed with approximately 20 moles of ethylene oxide)
were tested topically at five concentrations in a guinea pig dermatophyte model against Trichophyton mentagrophytes. Seven animals per concentration were infected with T. mentagrophytes and then treated with the commercial cream base or a cream base within the scope of those in Table I. The infected areas were cultured, and the plates were examined after four and eight days incubation. The cultures were scored as 0 if negative after eight days, as 2 if positive after four days and as 1 if negative after four days and positive after eight days. The percent cultures negative were calculated daily for each group as ##EQU1## These data are presented in Tables II and III. For both groups, graphs of percent cultures negative versus time were prepared. The areas under the curves (AUC's) were calculated by the trapezoidal rule. The AUC divided by the maximum possible AUC.times.100 was also calculated to give the percent AUC. A probit analysis of the percent AUC versus dose was used to determine the ED.sub.90 (see FIG. 1 and Table IV).
TABLE II__________________________________________________________________________SCORES WITH 0.1%-0.02% CLOTRIMAZOLE IN THE KNOWNCOMMERCIAL OIL-IN-WATER EMULSION CREAM BASE FORMULATION__________________________________________________________________________0.1% 0.08%day 7 animals Score day 7 animals Score__________________________________________________________________________2 0 0 1 0 0 0 1 86 2 1 1 1 2 0 0 0 644 0 0 0 0 0 1 0 93 4 0 0 1 0 1 1 2 647 0 0 0 0 0 0 0 100 7 0 1 1 0 0 0 0 869 0 0 0 0 0 0 0 100 9 0 0 1 1 0 0 0 8611 0 0 0 0 0 0 0 100 11 0 1 1 0 0 0 0 8614 0 0 0 0 0 0 0 100 14 0 0 0 0 0 0 0 10016 0 0 0 0 0 0 0 100 16 0 0 0 0 0 0 1 93__________________________________________________________________________0.06% 0.04%day 7 animals Score day 7 animals Score__________________________________________________________________________2 0 1 1 1 1 0 2 57 2 2 2 2 2 2 2 2 04 1 2 1 2 2 2 1 21 4 2 2 2 2 2 2 2 07 0 0 1 1 0 0 0 86 7 0 0 2 0 0 0 0 869 0 1 2 2 0 0 0 64 9 0 0 2 0 0 0 2 7111 0 0 1 0 0 0 0 93 11 0 0 0 0 0 0 0 10014 0 0 0 0 0 0 0 100 14 0 0 0 0 0 0 0 10016 0 2 0 0 0 0 0 86 16 0 0 2 0 0 1 2 64__________________________________________________________________________ 0.02% day 7 animals Score__________________________________________________________________________ 2 2 2 2 2 2 2 2 0 4 2 2 2 2 2 2 2 0 7 0 2 2 0 2 2 2 29 9 2 2 2 2 2 2 2 0 11 0 0 0 0 0 0 2 86 14 0 0 0 0 0 0 0 100 16 0 2 2 0 0 0 0 57__________________________________________________________________________
TABLE III__________________________________________________________________________SCORES WITH 0.08%-0.01% CLOTRIMAZOLE IN THE OIL-IN-WATEREMULSION CREAM BASE FORMULATIONS OF THIS INVENTION__________________________________________________________________________0.08% 0.06%day 7 animals Score day 7 animals Score__________________________________________________________________________2 0 0 0 0 0 0 0 100 2 0 0 0 0 0 0 0 1004 0 0 0 0 0 0 0 100 4 0 0 0 0 0 0 0 1007 0 0 0 0 0 0 0 100 7 0 0 0 0 0 0 0 1009 0 0 0 0 0 0 0 100 9 0 0 0 0 0 0 0 10011 0 0 0 0 0 0 0 100 11 0 0 0 0 0 0 0 10014 0 0 0 0 0 0 0 100 14 0 0 0 0 0 0 0 10016 0 0 0 0 0 0 0 100 16 0 0 0 0 0 0 0 100__________________________________________________________________________0.04% 0.02%day 7 animals Score day 7 animals Score__________________________________________________________________________2 0 1 1 0 0 0 1 79 2 2 2 2 2 1 2 0 214 0 0 0 0 0 0 1 93 4 0 0 0 0 1 0 1 867 0 0 0 0 0 0 0 100 7 1 2 1 0 0 0 0 719 0 0 0 0 0 0 0 100 9 0 0 0 0 0 0 0 10011 0 0 0 0 0 0 0 100 11 0 0 0 1 0 1 0 8614 0 0 0 0 0 0 0 100 14 0 0 0 0 0 0 0 10016 0 0 0 0 0 0 0 100 16 0 0 0 0 0 0 0 100__________________________________________________________________________ 0.01% day 7 animals Score__________________________________________________________________________ 2 2 2 2 2 2 2 2 0 4 2 1 2 2 0 2 0 36 7 2 2 1 2 2 1 2 14 9 1 0 0 2 0 2 0 64 11 0 0 0 0 0 0 0 100 14 0 0 0 0 0 0 0 100 16 0 0 0 0 0 2 0 86__________________________________________________________________________
TABLE IV______________________________________IN VIVO ANTIFUNGAL POTENCY IN THEGUINEA PIG DERMATOPHYTE MODEL ED.sub.90 (%) DoseVehicle Exp. 1 Exp. 2______________________________________Commercial oil-in-water 0.095 0.060emulsion cream baseCream base of this invention 0.029 0.027______________________________________
As can be noted above (FIG. 1 and Table IV), clotrimazole in the cream base formulation of this invention exhibits about 2 to 3 times greater in vivo potency when topically applied than the same dose of clotrimazole administered in a commercial oil-in-water emulsion cream base formulation.
Optional additional pharmaceutically acceptable ingredients can be included in the composition of this invention such as: mineral oil, benzyl alcohol, anhydrous dibasic sodium phosphate, monobasic sodium phosphate, and other commonly used buffers and preservatives. The pH of the formulation is most preferable at a pH range of 5-7.
The following examples illustrate the invention.
EXAMPLE I
An oil-in-water antifungal cream emulsion, i.e. a spreadable semi-solid, is prepared from the following ingredients:
______________________________________Ingredient Amount (mg/g)______________________________________Clotrimazole 40.00White petrolatum, USP 150.00Mineral oil, USP 60.00Cetearyl alcohol 72.00Ceteth 20 22.50Benzyl alcohol, NF 10.00Propylene glycol, USP 100.00Anhydrous dibasic 0.35sodium phosphateMonobasic sodium 5.00phosphate monohydrateWater q.s. to 1 g______________________________________
Procedure
Heat 75% of the water to 70.degree. C. in a suitable vessel. Add the monobasic sodium phosphate monohydrate, anhydrous dibasic sodium phosphate, propylene glycol, and benzyl alcohol to the vessel with agitation, maintaining the temperature at 70.degree. C.
In a separate vessel, melt the petrolatum and heat to 70.degree. C. Add the mineral oil and mix. Add the cetearyl alcohol and 95% of the ceteth 20; mix and maintain 70.degree. C.
Combine the contents of the 2 vessels with agitation, maintaining 70.degree. C.
Cool to 38.degree. C. with agitation.
In a separate vessel dissolve the remaining ceteth 20 in the remaining water at 65.degree. C. with agitation. Cool to room temperature and slurry the clotrimazole with vigorous agitation until a smooth uniform slurry is obtained.
Add the slurry to the previous emulsion mixture and agitate while cooling to room temperature.
EXAMPLE II
An oil-in-water emulsion in the form of a liquid antifungal lotion is prepared from the following ingredients:
______________________________________Ingredient Amount (mg/g)______________________________________Clotrimazole 40.00White petrolatum, USP 50.00Mineral oil, USP 20.00Cetearyl alcohol 24.00Ceteth 20 22.50Benzyl alcohol, NF 10.00Propylene glycol, USP 100.00Anhydrous dibasic 0.35sodium phosphateMonobasic sodium 5.00phosphate, monohydrateWater q.s. for 1 g______________________________________
The ingredients are combined according to the procedure for Example I.
Formulations I through XVII are prepared according to the procedure for Example I.
Claims
  • 1. An oil-in-water cream base antifungal percutaneous composition comprising:
  • ______________________________________0.5 mg clotrimazole;150 mg petrolatum;72 mg cetearyl alcohol;100 mg propylene glycol;22.5 mg ceteth-2060 mg mineral oil10 mg benzyl alcohol;0.35 mg anhydrous dibasic sodium phosphate;5 mg monobasic sodium phosphate; andwater q.s. to 1 gram.______________________________________
  • 2. An oil-in-water cream base anti-fungal percutaneous composition comprising:
  • ______________________________________0.1 mg clotrimazole;150 mg petrolatum;72 mg cetearyl alcohol;100 mg propylene glycol;22.5 mg ceteth-20;60 mg mineral oil;10 mg benzyl alcohol;0.35 mg anhydrous dibasic sodium phosphate;5 mg monobasic sodium phosphate; andwater q.s. to 1 gram______________________________________
  • 3. An oil-in-water cream base antifungal percutaneous composition comprising the following ingredients in the indicated proportions:
  • ______________________________________(a) 0.1 to 100 mg clotrimazole;(b) 100 to 300 mg petrolatum;(c) 50 to 120 mg cetearyl alcohol;(d) 50 to 200 mg propylene glycol;(e) 15 to 30 mg ceteth 20; and(f) pharmaceutically acceptable aqueous solvents to 1 gram.______________________________________
Parent Case Info

This application is a continuation-in-part of applicant's co-pending U.S. patent application Ser. No. 656,217, filed Oct. 1, 1984 abandoned.

US Referenced Citations (2)
Number Name Date Kind
3660577 Buchel et al. May 1972
4444762 Rajadhyaksha Apr 1984
Non-Patent Literature Citations (1)
Entry
Physicians Desk Reference, 31st ed., 1977, p. 750.
Continuation in Parts (1)
Number Date Country
Parent 656217 Oct 1984